Antisense treatment of viral infection.
In this chapter I have attempted to outline the rationale that underlies the antisense approach to treatment of virus infection, to catalog the effector molecules that are currently available, and to estimate the relative worth of each. In so doing I have tried to describe the criteria that might be employed in their design and the factors that may determine their efficacy in tissue culture and, perhaps, in vivo. Finally, I have described the few examples presently available that indicate that antisense approaches may one day be therapeutically useful in treatment of disease of viral or nonviral origin.
Whitton
J L
JL
Department of Neuropharmacology, Scripps Research Institute, La Jolla, California 92037.
D000818:Animals; D001483:Base Sequence; D006801:Humans; D008969:Molecular Sequence Data; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use*; D016372:RNA, Antisense / Q000627:therapeutic use*; D016337:RNA, Catalytic / Q000008:administration & dosage / Q000502:physiology / Q000627:therapeutic use*; D014777:Virus Diseases / Q000628:therapy*
D016376:Oligonucleotides, Antisense; D016372:RNA, Antisense; D016337:RNA, Catalytic